Incyte Corp

Incyte’s FrontMIND data shows tafasitamab + lenalidomide boosts PFS in first‑line DLBCL, giving a strong value‑based case for payers and a clear path to profitability.

Incyte’s new approvals of Minjuvi and Zynyz in Japan boost its oncology portfolio, delivering dual‑targeted therapies with strong cost‑effectiveness and high profit margins.

Incyte’s Breakthrough Therapy and Fast‑Track designations for INCA033989 unlock a $2‑$3 billion market, offering a novel calreticulin‑targeting antibody that could reshape myeloproliferative neoplasm treatment and boost shareholder value.

Incyte Corp: Institutional leaders spot a breakout‑potential as its small‑molecule oncology pipeline and hedge‑fund backing signal solid upside.

Incyte’s Q3 revenue jumps 20% thanks to Jakafi’s strong sales, highlighting its expanding indication portfolio and promising pipeline for future growth.

Incyte Corporation has announced positive results from a Phase 3b trial of its drug Opzelura (ruxolitinib cream) for moderate atopic dermatitis, potentially expanding the treatment’s indications beyond its current use for alopecia areata and pediatr…

Incyte Corporation’s oncology pipeline has shown promising results in Phase 1 studies, with two candidates, INCA33890 and a KRAS G12D inhibitor, demonstrating efficacy in microsatellite stable colorectal cancer and advanced pancreatic ductal adenoca…

Incyte Corporation is set to present pivotal Phase 1 data on its bispecific antibody INCA33890 and KRAS G12D inhibitor INCB161734 at the European Society of Medical Oncology (ESMO) Congress 2025, which could have significant implications for the com…

Incyte Corporation’s share price has surged due to its strategic focus on proprietary small-molecule therapeutics, particularly the CALR antibody program, which has positioned the company as a top performer in the S&P 500 healthcare sector.

Incyte Corporation has announced advancements in its dermatology pipeline, including new clinical data and the addition of late-stage dermatology programs, ahead of the European Association of Dermatology and Venereology (EADV) 2025 Congress.